AAM Speaks Out Against Build Back Better Bill

US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers

 
• By Chloe Kent
  
Joe Biden Build Back Better
Biden's Build Back Better Bill Has Been Criticized By The AAM • Source: Alamy

More from Policy & Regulation

More from Generics Bulletin